UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2289

2023

Volltextzugriff (PDF)

MS-275, a potent orally available inhibitor of histone deacetylases—The development of an anticancer agent

The international journal of biochemistry & cell biology, 2007-01, Vol.39 (7-8), p.1388-1405

2007

Volltextzugriff (PDF)

Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses

Clinical and experimental medicine, 2023-12, Vol.23 (8), p.5445-5461

2023

Volltextzugriff (PDF)

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Molecular oncology, 2024-03, Vol.18 (3), p.726-742

2024

Volltextzugriff (PDF)

Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues

Biochemical journal, 2002-02, Vol.362 (Pt 1), p.155-164

2002

Volltextzugriff (PDF)

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

BMC cancer, 2016-08, Vol.16 (1), Article 622

2016

Volltextzugriff (PDF)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

International journal of cancer, 2019-09, Vol.145 (5), p.1346-1357

2019

Volltextzugriff (PDF)

Alternative versus classical activation of macrophages

Pathobiology (Basel), 1999-01, Vol.67 (5-6), p.222-226

1999

Volltextzugriff (PDF)

AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

BMC cancer, 2016-08, Vol.16, p.622-622

2016

Volltextzugriff (PDF)

AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

BMC cancer, 2016-08, Vol.16 (1)

2016

Volltextzugriff (PDF)

Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6031-6031

2019

Volltextzugriff (PDF)

Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma

International journal of oncology, 2019-03, Vol.54 (3), p.1123-1133

2019

Volltextzugriff (PDF)

Abstract 4779: Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitro

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4779-4779

2018

Volltextzugriff (PDF)

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

British journal of haematology, 2024-01, Vol.204 (1), p.191-205

2024

Volltextzugriff (PDF)

Abstract 4793: Preclinical evaluation of the combination rogaratinib and copanlisib in HNSCC and HCC in preclinical in vitro and in vivo models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4793-4793

2019

Volltextzugriff (PDF)

Abstract A115: Mechanisms of resistance toward the FGFR inhibitor rogaratinib in preclinical urothelial bladder cancer models

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A115-A115

2019

Volltextzugriff (PDF)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

Oncotarget, 2020-10, Vol.11 (41), p.3688-3697

2020

Volltextzugriff (PDF)

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

International journal of cancer, 2017-01, Vol.140 (2), p.449-459

2017

Volltextzugriff (PDF)

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Molecular cancer therapeutics, 2020-06, Vol.19 (6), p.1289-1297

2020

Volltextzugriff (PDF)

A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies

Molecular cancer therapeutics, 2023-09, Vol.22 (9), p.1073-1086

2023

Volltextzugriff (PDF)

Abstract 4781: Changes in intracellular signaling following chronic FGFR inhibition in urothelial bladder cancer models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4781-4781

2018

Volltextzugriff (PDF)

Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3080-3080

2019

Volltextzugriff (PDF)

Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/p-catenin pathway in xenograft models of hepatocellular carcinoma

International journal of oncology, 2019-03, Vol.54 (3), p.1123

2019

Volltextzugriff (PDF)

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.651-651

2022

Volltextzugriff (PDF)

Abstract 1079: Preclinical activity of the FGFRinhibitor BAY 1163877 alone or in combination with antihormonal therapy in breast cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1079-1079

2017

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

MS-275, a potent orally available inhibitor of histone deacetylases—The development of an anticancer agent

Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Alternative versus classical activation of macrophages

AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC

Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma

Abstract 4779: Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitro

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

Abstract 4793: Preclinical evaluation of the combination rogaratinib and copanlisib in HNSCC and HCC in preclinical in vitro and in vivo models

Abstract A115: Mechanisms of resistance toward the FGFR inhibitor rogaratinib in preclinical urothelial bladder cancer models

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies

Abstract 4781: Changes in intracellular signaling following chronic FGFR inhibition in urothelial bladder cancer models

Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models

Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/p-catenin pathway in xenograft models of hepatocellular carcinoma

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

Abstract 1079: Preclinical activity of the FGFRinhibitor BAY 1163877 alone or in combination with antihormonal therapy in breast cancer

Suchergebnisse filtern